Glypican 3 (GPC3) is a cell surface glycoprotein that has emerged as a potential target in HCC; accordingly, it was detected by IHC in all patients in the Haines et al. cohort, including patients with and without underlying liver conditions [33,61,62]. Here, GPC3 is linked to hepatocellular carcinoma.